Article Text

other Versions

PDF
Systematic review
Treatment of hepatitis C, then, now and tomorrow
  1. Richard K Sterling,
  2. Narayan Dharel
  1. Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, West Hospital, Richmond, Virginia, USA
  1. Correspondence to : Dr Richard K Sterling, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, West Hospital, 14th Floor, 1200 East Broad Street, PO Box 980341, Richmond, VA 23298-0341, USA; rksterli{at}vcu.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Hepatitis C virus (HCV) infects over 185 million people worldwide and can lead to progressive liver fibrosis, cirrhosis, hepatocellular carcinoma and death. Antiviral treatment can prevent these complications and improve survival. Interferon has been the backbone of anti-HCV therapy, but has been plagued by side effects, treatment failure and relapse. HCV treatment has seen significant changes with the advent of directly acting antiviral agents with nearly 100% cure rate with all oral, interferon and ribavirin-free regimens.

Methods

This systematic review of randomised controlled trials (RCTs) and cohort studies aimed to examine the safety, tolerability and efficacy of all Food and Drug Administration (FDA)-approved regimens against HCV genotypes 1, 2 and 3. All studies between January 2009 and May 2014 were included if they were published in English, used FDA-approved antiviral therapies, included sustained virological response (SVR) as the study outcome, and defined treatment experience …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.